BMS453 (Standard)
BMS453 (Standard) is the analytical standard of BMS453. This product is intended for research and analytical applications. BMS453 (BMS-189453), a synthetic retinoid, is a RARβ agonist and a RARα/RARγ antagonist. BMS453 inhibits breast cell growth predominantly through the induction of active TGFβ[1][2].
Product Specifications
CAS Number
166977-43-1
Target
RAR/RXR; Reference Standards
Related Pathways
Metabolic Enzyme/Protease; Others; Vitamin D Related/Nuclear Receptor
Field of Research
Cancer
Smiles
O=C(O)C1=CC=C(/C=C/C2=CC=C3C(C)(C)CC=C(C4=CC=CC=C4)C3=C2)C=C1
Molecular Formula
C27H24O2
Molecular Weight
380.48
References & Citations
[1]J Y Chen, et al. RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J. 1995 Mar 15;14 (6) :1187-97.|[2]L Yang, et al. The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGFbeta and causing cell cycle arrest. Oncogene. 2001 Nov 29;20 (55) :8025-35.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400977-500 1x 500 µL
TGF-beta (1D11.16.8), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680181-100 1x 100 µL
CD59 (heavy chain of Protectin) (BRA-10G), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940630-100 1x 100 µL
Mucin 1 / EMA / Episialin / CD227 (VU-2G7), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470391-100 1x 100 µL
CD81 / TAPA-1 (1.3.3.22), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details